Skip Navigation
Find a Doctor
 
 
 
 

 

Photo of Dr. William Matsui

William Hikaru Matsui, MD

Associate Professor of Oncology
Professor of Oncology
Male
Appointment Phone

410-955-8964

Main Location

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

View All Locations
Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-0773 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »

Titles

  • Associate Professor of Oncology
  • Professor of Oncology

Centers & Institutes

  • Matsui Laboratory at Sidney Kimmel Comprehensive Cancer Center
  • Sidney Kimmel Comprehensive Cancer Center

Expertise

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Hodgkin's Disease, Leukemia, Lymphoma, Medical Oncology, Multiple Myeloma, Non-Hodgkin's Lymphoma, Pancreatic Cancer

Research Interests

Hematologic Malignancies, Stem Cells

Biography

William Matsui, M.D., received his undergraduate degree in biochemistry from Harvard College and his M.D. from the University of California, San Francisco. He completed his internship and residency in internal medicine at the University of Washington in Seattle and fellowship training in medical oncology at Johns Hopkins University. At the completion of his fellowship in 2002, he joined the faculty as an assistant professor at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine. He was subsequently promoted to the rank of associate professor in 2008.

Dr. Matsuis current research is focused on normal and cancer stem cell biology. His laboratory identified tumor-initiating cells in the plasma cell malignancy multiple myeloma in 2004. He has subsequently found that these cells share several cellular processes with normal stem cells that regulate self-renewal and drug resistance. Recently, his laboratory has expanded these studies and studied human pancreatic cancers and normal hematopoiesis. Dr. Matsui he has been awarded the George Santos Research Award from the Leukemia and Lymphoma Society, the Clinician Scientist Award from Johns Hopkins University, and teaching awards from the Departments of Oncology and Medicine.

Dr. Matsui clinically specializes in caring for adults with hematologic malignancies and in bone marrow transplantation. In addition to his basic studies, his lab also focuses on translational research and the development of novel therapies that target cancer stem cells in hematologic malignancies. More than a dozen clinical trials have been initiated based on his labs preclinical work.

Languages

  • English

Memberships

American Society of Clinical Oncology
American Society of Hematology
American Association of Cancer Research
American Society for Blood and Marrow Transplantation
International Society for Stem Cell Research

Additional Resources

Additional Resources +
  • Education +

    Training

    • University of California San Francisco (San Francisco CA ) (1995)

    Residencies

    • University of Washington School of Medicine / Internal Medicine (Seattle WA ) (1998)

    Fellowships

    • Johns Hopkins University School of Medicine / Oncology (Baltimore MD ) (2001)
    • Johns Hopkins University School of Medicine / Oncology (Baltimore MD ) (2000)
  • Research & Publications +

    Selected Publications

    Research Summary

    In an increasing number of human malignancies, tumorigenic potential may be restricted to phenotypically and functionally distinct populations of cancer stem cells. Dr. Matsuis laboratory has studied multiple myeloma and found that the neoplastic plasma cells which characterize the disease are terminally differentiated and lack substantial proliferative potential. Instead, these mature tumor cells appear to arise from a relatively small population of tumor cells resembling normal memory B cells with the ability to both differentiate and self-renew. His laboratory subsequently demonstrated that most agents currently used to treat multiple myeloma patients are able to effectively inhibit plasma cells but are inactive against myeloma stem cells. These findings potentially explain why many current therapies are capable of producing clinical responses seen as decreased numbers of plasma cells but rarely cure the disease since myeloma stem cells may be spared and mediate tumor regrowth and clinical relapse. Dr. Matsuis laboratory has expanded these findings to other human tumors and has recently identified tumorigenic cell populations in Hodgkin lymphoma and pancreatic adenocarcinoma.

    Self-renewal is the cellular process that likely maintains the malignant clone, and the Matsui lab has examined whether specific cellular pathways that mediate this property can serve as novel therapeutic targets. To this end, his laboratory has found that the Hedgehog signaling pathway required for proper embryonic development may regulate cancer stem cells in multiple myeloma, pancreatic cancer and brain tumors. His laboratory has also developed strategies based eliminating self-renewal potential through the forced induction of terminal differentiation. The Matsui group has successfully transformed these laboratory results into several novel clinical trials for patients with multiple myeloma, Hodgkin lymphoma, and myeloid leukemias. Finally, as a critical part of these clinical trials, we have begun to develop novel biomarkers strategies to quantify cancer stem cells in patients undergoing treatment.

    Journal Citations

    Fan, X.; Matsui, W.; Khaki, L.; Stearns, D.; Chun, J.; Li, Y.M.; Eberhart, C.G. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 2006 Aug 1;66(15):7445-7452.

    Huff, C.A.; Fuchs, E.J.; Smith, B.D.; Blackford, A.; Garrett-Mayer, E.; Brodsky, R.A.; Flinn, I.W.; Ambinder, R.F.; Borrello, I.M.; Matsui, W.H.; Vogelsang, G.B.; Griffin, C.A.; Luznik, L.; Jones, R.J. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant. 2006 Apr;12(4):414-421.

    Huff, C.A.; Matsui, W.; Smith, B.D.; Jones, R.J. The paradox of response and survival in cancer therapeutics. Blood. 2006 Jan 15;107(2):431-434.

    Huff, C.A.; Matsui, W.H.; Douglas Smith, B.; Jones, R.J. Strategies to eliminate cancer stem cells: clinical implications. Eur J Cancer. 2006 Jun;42(9):1293-1297.

    Matsui, W.H.; Brodsky, R.A.; Smith, B.D.; Borowitz, M.J.; Jones, R.J. Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Leukemia. 2006 Mar;20(3):458-462.

    Bar, E.E.; Chaudhry, A.; Lin, A.; Fan, X.; Schreck, K.; Matsui, W.; Piccirillo, S.; Vescovi, A.L.; DiMeco, F.; Olivi, A.; Eberhart, C.G. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells. 2007 Oct;25(10):2524-2533.

    Bolanos-Meade, J.; Garrett-Mayer, E.; Luznik, L.; Anders, V.; Webb, J.; Fuchs, E.J.; Huff, C.A.; Matsui, W.; Borrello, I.M.; Brodsky, R.; Kasamon, Y.L.; Swinnen, L.J.; Flinn, I.W.; Ambinder, R.F.; Jones, R.J.; Hess, A.D.; Vogelsang, G.B. Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. Biol Blood Marrow Transplant. 2007 Oct;13(10):1185-1191.

    Chumsri, S.; Matsui, W.; Burger, A.M. Therapeutic implications of leukemic stem cell pathways. Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6549-6554.

    Lin, T.L.; Vala, M.S.; Barber, J.P.; Karp, J.E.; Smith, B.D.; Matsui, W.; Jones, R.J. Induction of acute lymphocytic leukemia differentiation by maintenance therapy. Leukemia. 2007 Sep;21(9):1915-1920.

    Peacock, C.D.; Wang, Q.; Gesell, G.S.; Corcoran-Schwartz, I.M.; Jones, E.; Kim, J.; Devereux, W.L.; Rhodes, J.T.; Huff, C.A.; Beachy, P.A.; Watkins, D.N.; Matsui, W. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4048-4053.

    Huff, C.A.; Matsui, W. Multiple myeloma cancer stem cells. J Clin Oncol. 2008 Jun 10;26(17):2895-2900.

    Lauring, J.; Abukhdeir, A.M.; Konishi, H.; Garay, J.P.; Gustin, J.P.; Wang, Q.; Arceci, R.J.; Matsui, W.; Park, B.H. The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood. 2008 Jan 15;111(2):856-864.

    Luznik, L.; O'Donnell, P.V.; Symons, H.J.; Chen, A.R.; Leffell, M.S.; Zahurak, M.; Gooley, T.A.; Piantadosi, S.; Kaup, M.; Ambinder, R.F.; Huff, C.A.; Matsui, W.; Bolanos-Meade, J.; Borrello, I.; Powell, J.D.; Harrington, E.; Warnock, S.; Flowers, M.; Brodsky, R.A.; Sandmaier, B.M.; Storb, R.F.; Jones, R.J.; Fuchs, E.J. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008 Jun;14(6):641-650.

    Matsui, W.; Wang, Q.; Barber, J.P.; Brennan, S.; Smith, B.D.; Borrello, I.; McNiece, I.; Lin, L.; Ambinder, R.F.; Peacock, C.; Watkins, D.N.; Huff, C.A.; Jones, R.J. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008 Jan 1;68(1):190-197.

    Warlick, E.D.; O'Donnell, P.V.; Borowitz, M.; Grupka, N.; Decloe, L.; Garrett-Mayer, E.; Borrello, I.; Brodsky, R.; Fuchs, E.; Huff, C.A.; Luznik, L.; Matsui, W.; Ambinder, R.; Jones, R.J.; Douglas Smith, B. Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leuk Res. 2008 Sep;32(9):1439-1447.

    Bolanos-Meade, J.; Luznik, L.; Muth, M.; Matsui, W.H.; Huff, C.A.; Smith, B.D.; Levy, M.Y.; Kasamon, Y.L.; Swinnen, L.J.; Powell, J.D.; Brodsky, R.A.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. Bone Marrow Transplant. 2009 Mar;43(6):477-480.

    Brandt, W.D.; Matsui, W.; Rosenberg, J.E.; He, X.; Ling, S.; Schaeffer, E.M.; Berman, D.M. Urothelial carcinoma: stem cells on the edge. Cancer Metastasis Rev. 2009 Dec;28(3-4):291-304.

    Ghosh, N.; Matsui, W. Cancer stem cells in multiple myeloma. Cancer Lett. 2009 May 8;277(1):1-7.
    He, X.; Marchionni, L.; Hansel, D.E.; Yu, W.; Sood, A.; Yang, J.; Parmigiani, G.; Matsui, W.; Berman, D.M. Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma. Stem Cells. 2009 Jul;27(7):1487-1495.

    Jiang, T.; Collins, B.J.; Jin, N.; Watkins, D.N.; Brock, M.V.; Matsui, W.; Nelkin, B.D.; Ball, D.W. Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer. Cancer Res. 2009 Feb 1;69(3):845-854.

    Jones, R.J.; Gocke, C.D.; Kasamon, Y.L.; Miller, C.B.; Perkins, B.; Barber, J.P.; Vala, M.S.; Gerber, J.M.; Gellert, L.L.; Siedner, M.; Lemas, M.V.; Brennan, S.; Ambinder, R.F.; Matsui, W. Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood. 2009 Jun 4;113(23):5920-5926.

    Kasamon, Y.L.; Luznik, L.; Leffell, M.S.; Kowalski, J.; Tsai, H.L.; Bolanos-Meade, J.; Morris, L.E.; Crilley, P.A.; O'Donnell, P.V.; Rossiter, N.; Huff, C.A.; Brodsky, R.A.; Matsui, W.H.; Swinnen, L.J.; Borrello, I.; Powell, J.D.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. Nonmyeloablative HLA-Haploidentical BMT with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome. Biol Blood Marrow Transplant. 2009 Nov 16.Merchant, A.A.; Matsui, W. Smoothening the controversial role of hedgehog in hematopoiesis. Cell Stem Cell. 2009 Jun 5;4(6):470-471.

    Mullendore, M.E.; Koorstra, J.B.; Li, Y.M.; Offerhaus, G.J.; Fan, X.; Henderson, C.M.; Matsui, W.; Eberhart, C.G.; Maitra, A.; Feldmann, G. Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clin Cancer Res. 2009 Apr 1;15(7):2291-2301.

    Savage, W.J.; Barber, J.P.; Mukhina, G.L.; Hu, R.; Chen, G.; Matsui, W.; Thoburn, C.; Hess, A.D.; Cheng, L.; Jones, R.J.; Brodsky, R.A. Glycosylphosphatidylinositol-anchored protein deficiency confers resistance to apoptosis in PNH. Exp Hematol. 2009 Jan;37(1):42-51.

    Sun, P.; Xia, S.; Lal, B.; Eberhart, C.G.; Quinones-Hinojosa, A.; Maciaczyk, J.; Matsui, W.; Dimeco, F.; Piccirillo, S.M.; Vescovi, A.L.; Laterra, J. DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation. Stem Cells. 2009 Jul;27(7):1473-1486.

    Tjiang, T.; B.J., C.; Jin, N.; Brock, M.V.; Watkins, D.N.; Matsui, W.; Nelkin, B.D.; Ball, D.W. ASCL1 regulates CD133 and tumor-initiating capacity of SCLC. Cancer Research. 2009 (In Press).

    Agarwal, J.R.; Matsui, W. Multiple myeloma: a paradigm for translation of the cancer stem cell hypothesis. Anticancer Agents Med Chem. 2010 Feb;10(2):116-120.

    Bar, E.E.; Lin, A.; Mahairaki, V.; Matsui, W.; Eberhart, C.G. Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am J Pathol. 2010 Sep;177(3):1491-1502.

    Brennan, S.K.; Meade, B.; Wang, Q.; Merchant, A.A.; Kowalski, J.; Matsui, W. Mantle cell lymphoma activation enhances bortezomib sensitivity. Blood. 2010 Nov 18;116(20):4185-4191.

    Brennan, S.K.; Wang, Q.; Tressler, R.; Harley, C.; Go, N.; Bassett, E.; Huff, C.A.; Jones, R.J.; Matsui, W. Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. PLoS One. 2010;5(9).

    Brodsky, R.A.; Chen, A.R.; Dorr, D.; Fuchs, E.J.; Huff, C.A.; Luznik, L.; Smith, B.D.; Matsui, W.H.; Goodman, S.N.; Ambinder, R.F.; Jones, R.J. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood. 2010 Mar 18;115(11):2136-2141.

    Ishizawa, K.; Rasheed, Z.A.; Karisch, R.; Wang, Q.; Kowalski, J.; Susky, E.; Pereira, K.; Karamboulas, C.; Moghal, N.; Rajeshkumar, N.V.; Hidalgo, M.; Tsao, M.; Ailles, L.; Waddell, T.K.; Maitra, A.; Neel, B.G.; Matsui, W. Tumor-initiating cells are rare in many human tumors. Cell Stem Cell. 2010 Sep 3;7(3):279-282.

    Kasamon, Y.L.; Jones, R.J.; Brodsky, R.A.; Fuchs, E.J.; Matsui, W.; Luznik, L.; Powell, J.D.; Blackford, A.L.; Goodrich, A.; Gocke, C.D.; Abrams, R.A.; Ambinder, R.F.; Flinn, I.W. Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma. Ann Oncol. 2010 Jun;21(6):1203-1210.

    Kasamon, Y.L.; Luznik, L.; Leffell, M.S.; Kowalski, J.; Tsai, H.L.; Bolanos-Meade, J.; Morris, L.E.; Crilley, P.A.; O'Donnell, P.V.; Rossiter, N.; Huff, C.A.; Brodsky, R.A.; Matsui, W.H.; Swinnen, L.J.; Borrello, I.; Powell, J.D.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010 Apr;16(4):482-489.

    Lim, Y.; Matsui, W. Hedgehog signaling in hematopoiesis. Crit Rev Eukaryot Gene Expr. 2010;20(2):129-139.

    Luznik, L.; Bolanos-Meade, J.; Zahurak, M.; Chen, A.R.; Smith, B.D.; Brodsky, R.; Huff, C.A.; Borrello, I.; Matsui, W.; Powell, J.D.; Kasamon, Y.; Goodman, S.N.; Hess, A.; Levitsky, H.I.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010 Apr 22;115(16):3224-3230.

    Merchant, A.; Joseph, G.; Wang, Q.; Brennan, S.; Matsui, W. Gli1 regulates the proliferation and differentiation of HSCs and myeloid progenitors. Blood. 2010 Mar 25;115(12):2391-2396.

    Merchant, A.A.; Matsui, W. Targeting Hedgehog-a cancer stem cell pathway. Clin Cancer Res. 2010 Jun 15;16(12):3130-3140.

    Ohm, J.E.; Mali, P.; Van Neste, L.; Berman, D.M.; Liang, L.; Pandiyan, K.; Briggs, K.J.; Zhang, W.; Argani, P.; Simons, B.; Yu, W.; Matsui, W.; Van Criekinge, W.; Rassool, F.V.; Zambidis, E.; Schuebel, K.E.; Cope, L.; Yen, J.; Mohammad, H.P.; Cheng, L.; Baylin, S.B. Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells. Cancer Res. 2010 Oct 1;70(19):7662-7673.

    Rajeshkumar, N.V.; Rasheed, Z.A.; Garcia-Garcia, E.; Lopez-Rios, F.; Fujiwara, K.; Matsui, W.H.; Hidalgo, M. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. Mol Cancer Ther. 2010 Sep;9(9):2582-2592.

    Rasheed, Z.; Wang, Q.; Matsui, W. Isolation of stem cells from human pancreatic cancer xenografts. J Vis Exp. 2010 (43).

    Rasheed, Z.A.; Yang, J.; Wang, Q.; Kowalski, J.; Freed, I.; Murter, C.; Hong, S.M.; Koorstra, J.B.; Rajeshkumar, N.V.; He, X.; Goggins, M.; Iacobuzio-Donahue, C.; Berman, D.M.; Laheru, D.; Jimeno, A.; Hidalgo, M.; Maitra, A.; Matsui, W. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst. 2010 Mar 3;102(5):340-351.

    Shim, J.S.; Matsui, Y.; Bhat, S.; Nacev, B.A.; Xu, J.; Bhang, H.E.; Dhara, S.; Han, K.C.; Chong, C.R.; Pomper, M.G.; So, A.; Liu, J.O. Effect of nitroxoline on angiogenesis and growth of human bladder cancer. J Natl Cancer Inst. 2010 Dec 15;102(24):1855-1873.

    Smith, B.D.; Jones, R.J.; Cho, E.; Kowalski, J.; Karp, J.E.; Gore, S.D.; Vala, M.; Meade, B.; Baker, S.D.; Zhao, M.; Piantadosi, S.; Zhang, Z.; Blumenthal, G.; Warlick, E.D.; Brodsky, R.A.; Murgo, A.; Rudek, M.A.; Matsui, W.H. Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF. Leuk Res. 2011 Jan;35(1):87-94.

    Huff, CA, Matsui, WH, Smith, BD, Jones, RJ. The paradox of response and survival in cancer therapeutics. Blood. 2006; 107:431-434.

    Matsui, W, Brodsky, RA, Smith, BD, Borowitz,MJ, Jones, RJ. Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Leukemia. 2006; 20:458-462.

    Huff, CA, Matsui, W, Smith, BD, Jones, RJ. Strategies to eliminate cancer stem cells: clinical implications. European Journal of Cancer. 2006; 42:1293-1297.

    Fan, X, Matsui, W, Khaki, L., Stearns, D., Chun, J., Li, YM., Eberhart, CG. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 2006; 66:7445-7452.

    Huff CA, Fuchs EJ, Smith BD, Blackford A, Garrett-Mayer, E, Brodsky RA, Flinn IW, Ambinder RF, Borrello IM, Matsui WH, Vogelsang GB, Griffin CA, Luznik L, Jones RJ. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biology of Blood and Marrow Transplantation. 2006; 12:414-421.

    Jones, R.J., Matsui, W. Cancer stem cells: from bench to bedside. Biology of Blood and Marrow Transplantation. 2007; 13 Suppl 1:47-52.

    Peacock, CD, Wang, Q, Gessell, GS, Corcoran-Scwartz, IM, Jones, E, Kim, J, Devereux, WL, Rhodes, JT, Huff, CA, Beachy, PA, Watkins, DN, Matsui, W. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proceedings of the National Academy of Sciences. 2007; 104:4048-4053.

    Feldmann, G, Dhara, S, Fendrich, V, Bedja, D, Beaty, R, Mullendore, M, Karikari, C, Alvarez, H, Iacobuzio-Donahue, C, Jimeno, A, Gabrielson, KL, Matsui, W, Maitra, A. Blockade of Hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Research. 2007; 67: 2187-96.

    Lin TL, Vala MS, Barber JP, Karp JE, Smith BD, Matsui W, Jones, RJ. Induction of acute lymphocytic leukemia differentiation by maintenance therapy. Leukemia. 2007; 21:1915-1920.

    Bar EE, Chaudhry A, Lin A, Fan X, Schreck K, Matsui W, Vescovi AL, Piccirillo S, Dimeco F, Olivi A, Eberhart CG. Cyclopamine-mediated Hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells. 2007; 25:2524-2533.

    Bolaos-Meade J, Garrett-Mayer E, Luznik L, Anders V, Webb J, Fuchs EJ, Huff CA, Matsui W, Borrello IM, Brodsky R, Kasamon YL, Swinnen LJ, Flinn IW, Ambinder RF, Jones RJ, Hess AD, Vogelsang GB. Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. Biology of Blood and Marrow Transplantation. 2007. 13:1185-1191.

    Chumsri S, Matsui W, Burger AM. Therapeutic Implications of Leukemic Stem Cell Pathways. Clinical Cancer Research. 2007; 13:6549-6554.

    Lauring J, Abukhdeir AM, Konishi H, Garay JP, Gustin JP, Wang Q, Arceci RJ, Matsui W, Park BH. The multiple myeloma-associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood. 2008; 111:856-864.

    Matsui W, Wang Q, Barber J, Brennan S, Smith B, Borrello I, McNiece I, Lin L, Ambinder R, Peacock C, Watkins N, Huff C, Jones R. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Research. 2008; 68:190-197.

    Warlick ED, ODonnell PV, Borowitz M, Grupka N, Decloe L, Garrett-Mayer E, Borrello I, Brodsky R, Fuchs E, Huff CA, Luznik L, Matsui W, Ambinder R, Jones RJ, Smith BD. Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leukemia Research. 2008; 32:1439-1447.

    Luznik L, O'Donnell P, Symons H, Chen A, Leffell M, Zahurak M, Gooley T, Piantadosi S, Kaup M, Ambinder RF, Huff CA, Matsui W, Bolaos-Meade J, Borrello I, Powell JD, Harrington E, Warnock S, Flowers M, Brodsky RA, Sandmaier BM, Storb RF, Jones RJ, Fuchs EJ. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biology of Blood and Marrow Transplantation. 2008; 14:641-650.

    Huff CA and Matsui W. Multiple myeloma cancer stem cells. Journal of Clinical Oncology. 2008; 28:2895-2900.

    Feldmann G, Fendrich V, McGovern K, Bedja D, Bisht S, Alvarez H, Koorstra J, Habbe N, Karikari C, Mullendore M, Gabrielson KL, Sharma R, Matsui W, Maitra A. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Molecular Cancer Therapeutics. 2008; 7:2725-2735.

    Ghosh N. and Matsui W. Cancer stem cells in multiple myeloma. Cancer Letters. 2008; 277:1-7.

    Bolaos-Meade J, Luznik L, Muth M, Matsui W, Huff CA, Smith BD, Levy MY, Kasamon YL, Swinnen L, Powell J, Brodsky R, Ambinder RF, Jones RJ, Fuchs EJ. Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. Bone Marrow Transplantation. 2009; 43:477-480.
  • Academic Affiliations & Courses +
  • Activities & Honors +

    Honors

    Kimmel Foundation Scholar. 2007-2009. Sidney Kimmel Foundation for Cancer Research.

    Leukemia and Lymphoma Society Scholar in Clinical Research. 2009-2014. The Leukemia and Lymphoma Society.
  • Videos & Media +
  • Events +
  • Contact & Locations +

    Locations

    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    401 N. Broadway
    Baltimore, MD 21231
    Phone: 410-955-2808
    Appointment Phone: 410-955-8964
    Fax: 410-614-7279
    Location Map

    Department/Division

    • Oncology

Is This You? Edit Profile

 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.